Get the Stockscreener App
1.07
0.00%
0.00
Cytosorbents Corp stock is traded at $1.07, with a volume of 85,186.
It is up +0.00% in the last 24 hours and down -18.32% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$1.07
Open:
$1.06
24h Volume:
85,186
Relative Volume:
0.33
Market Cap:
$66.71M
Revenue:
$33.79M
Net Income/Loss:
$-18.67M
P/E Ratio:
-2.9872
EPS:
-0.3582
Net Cash Flow:
$-19.17M
1W Performance:
+1.90%
1M Performance:
-18.32%
6M Performance:
-0.93%
1Y Performance:
+5.94%
1-Day Range:
$1.05
$1.101
1-Week Range:
$0.99
$1.101
52-Week Range:
$0.70
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
1.07 | 66.71M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
Cytosorbents (NASDAQ:CTSO) shareholders have endured a 78% loss from investing in the stock five years ago - Yahoo Finance
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
CytoSorbents Corp. to Host Earnings Call - ACCESS Newswire
CytoSorbents Corp (CTSO) Q4 2024 Earnings Report Preview: What T - GuruFocus.com
CytoSorbents Corp (CTSO) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Cytosorbents Corp Reaffirms Preliminary Financial Expectations For Q4 And FY 2024 -March 04, 2025 at 04:52 pm EST - Marketscreener.com
CytoSorbents delays earnings call after VP’s passing - Investing.com India
CytoSorbents Corporation Postpones Earnings Call Following Loss of Vice President and Corporate Controller - Nasdaq
CytoSorbents delays earnings call after VP’s passing By Investing.com - Investing.com Canada
CytoSorbents Delays Earnings But Confirms 25% Growth: What's Behind The Postponement? - StockTitan
Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com - Defense World
Cytosorbents (NASDAQ:CTSO) Earns “Buy” Rating from D. Boral Capital - Defense World
Cytosorbents (CTSO) to Release Quarterly Earnings on Thursday - Defense World
When Will CytoSorbents Release Q4 2024 Results? Key Date for Investors - StockTitan
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - Yahoo Finance
CytoSorbents secures $1.6 million from warrant exercises - Investing.com
CytoSorbents Secures $1.6M Capital InjectionWill This Fuel Their FDA Application Success? - StockTitan
Cytosorbents Co. (NASDAQ:CTSO) Sees Significant Increase in Short Interest - Defense World
B. Riley Securities initates Cytosorbents Corp (CTSO) rating to a Buy - Knox Daily
CTSO stock touches 52-week high at $1.6 amid robust annual growth - MSN
Cytosorbents (NASDAQ:CTSO) Stock Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Cytosorbents (NASDAQ:CTSO) Stock Passes Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com - Defense World
Sargent Investment Group LLC Sells 377,384 Shares of Cytosorbents Co. (NASDAQ:CTSO) - MarketBeat
Cytosorbents (NASDAQ:CTSO) Stock Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Vanguard Group Inc's Strategic Acquisition of CytoSorbents Corp Shares - GuruFocus.com
Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com - Defense World
Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com - MarketBeat
Chief Medical Officer Deliargyris Efthymios exercised 16,233 in-the-money shares at a strike of $1.00, increasing direct ownership by 4% to 403,025 units (SEC Form 4) - Quantisnow
CytoSorbents Strengthens Balance Sheet with Successful Conclusion of Rights Offering - Defense World
Cytosorbents Boosts Liquidity with Successful Rights Offering - Yahoo Finance
Cytosorbents (NASDAQ:CTSO) Given Buy Rating at D. Boral Capital - Defense World
CytoSorbents closes oversubscribed rights offering - MSN
D. Boral Capital Reiterates Buy Rating for Cytosorbents (NASDAQ:CTSO) - MarketBeat
Expert Outlook: CytoSorbents Through The Eyes Of 7 Analysts - Benzinga
CytoSorbents Raises $6.25M in Oversubscribed Rights Offering, Unlocks $5M Restricted Cash - StockTitan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Cytosorbents Co. (NASDAQ:CTSO) Stake Boosted by Geode Capital Management LLC - Defense World
Skylands Capital, LLC Increases Stake in CytoSorbents Corp - GuruFocus.com
Revenue Surge & Breakthrough Margins Fuel Growth in Critical Care Tech - Streetwise Reports
CytoSorbents opens new sales subsidiary in Dubai - Investing.com
CytoSorbents Expands Global Reach with Strategic Dubai Hub for Middle East & Africa Growth - StockTitan
CytoSorbents reported strong Q4 results, says D. Boral Capital - Yahoo Finance
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):